University of Mississippi

eGrove
Electronic Theses and Dissertations

Graduate School

2016

Effects Of Chronic Mild Stress On Clinically Relevant Endpoints In
A Rat Ntg Migraine Model
Mary Katherine Jourdan
University of Mississippi

Follow this and additional works at: https://egrove.olemiss.edu/etd
Part of the Cognitive Psychology Commons

Recommended Citation
Jourdan, Mary Katherine, "Effects Of Chronic Mild Stress On Clinically Relevant Endpoints In A Rat Ntg
Migraine Model" (2016). Electronic Theses and Dissertations. 1143.
https://egrove.olemiss.edu/etd/1143

This Thesis is brought to you for free and open access by the Graduate School at eGrove. It has been accepted for
inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more information,
please contact egrove@olemiss.edu.

EFFECTS OF CHRONIC MILD STRESS ON CLINICALLY RELEVANT ENDPOINTS IN A
RAT NTG MIGRAINE MODEL

A Thesis
Presented in partial fulfillment of requirements
For the degree of Master of Arts in the department of Psychology
The University of Mississippi

By
MARY K. JOURDAN
August 2016

Copyright Mary K. Jourdan 2016
ALL RIGHTS RESERVED

ABSTRACT

Migraineurs report stressors increase the frequency and intensity of migraine episodes.
Chronic migraineurs, compared to episodic migraineurs, report a higher comorbidity with stressrelated disorders. Rodent models of nitroglycerin-(NTG) induced migraine are a recent addition
in pain research; however, these models lack translational relevance in that behavioral endpoints
do not align with the clinical symptoms. In this laboratory, we have developed and continue to
validate a recurrent migraine model that better aligns with such clinical endpoints. The purpose
of this study was to explore whether migraine combined with a stress manipulation would
exacerbate respective behavioral endpoints associated with migraine and stress. This research
employed a 2x2 factorial design that combined two levels chronic mild stress (CMS vs no-CMS)
and two levels of migraine (5 NTG episodes vs no-NTG). Assays used to quantify stress and
migraine behavioral endpoints include: Elevated Plus Maze (EPM), Forced Swim Test (FST),
Rat Grimace Scale (RGS), light sensitivity and activity in a light/dark box, and Hotplate. CMS
manipulation induced an anxiety-like effect on EPM in both non-NTG and NTG groups;
however, CMS did not alter depressive-like behavior in FST in either non-NTG or NTG groups.
NTG manipulation altered the RGS scores in non-CMS and CMS groups; however, NTG did not
alter time in light portion or activity in light/dark box in either non-CMS or CMS groups. The
combination of CMS and NTG did not exacerbate either stress-related or migraine-related
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behaviors. These findings add another migraine model validation step and suggest the 5 NTG
protocol better mirrors episodic migraine rather than chronic migraine.
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CHAPTER 1

INTRODUCTION

Migraine is the 7th highest cause of disability and the 3rd most prevalent disorder in the
world (Martelletti et al., 2013). Fifty-three percent of individuals who suffer migraine report
severe impairment of daily activities. Further, migraines account for 51% reduction in work or
school productivity (Lipton et al., 2001) by contributing to 112 million bedridden days (Pryse –
Phillips, 2002) and $13 million worth of productivity lost in the workplace (Hu, 1999).
The International Classification of Headache Disorders 3rd edition (ICHD –3) describes
migraine as a recurrent unilateral pulsating or throbbing headache lasting between 4-72 hours.
Symptoms include photophobia (sensitivity to light), phonophobia (sensitivity to sound), nausea,
and vomiting with some patients reporting cutaneous allodynia during migraine episodes
(Silberstein, 2004). Migraine sufferers can be classified into two categories, episodic migraine
(i.e., < 15 episodes/month) or chronic migraine (i.e., > 15 episodes/month). Migraineurs are
more likely than non-migraineurs to have disabilities (Bigal et al., 2003) and higher
comorbidities with other psychiatric disorders (Blumenfeld et al., 2010; Smitherman et al., 2013)
including major depressive disorder, generalized anxiety disorder, panic disorder, social phobia,
and bipolar disorder (Baskin, Lipchik, & Smitherman, 2006; Baskin & Smitherman, 2009;
Breslau & Davis, 1993; Jette, et al., 2008; Swartz et al., 2000; Saunders et al., 2008;
Smitherman, 2015).
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Of these, stress related disorders, such as Generalized Anxiety Disorder, Panic Disorder
and Major Depressive Disorder, are most common in migraineurs with rates two to four times
higher than non-migraineurs (Jette et al., 2008; Lanteri-Minet et al., 2005). For example, higher
levels of stress have been shown to positively correlate with greater migraine frequency
(Schramm et al., 2014) and an increased risk of chronification (Smitherman et al., 2013).
Previous studies show a positive correlation between stress intensity and migraine frequency
(Schramm et al., 2014) with stress being a significant predictor of a headache episode (Turner et
al., 2014). While correlated, these disorders have distinct neuro-pathologies. This complex
relationship between anxiety and migraine makes treatment challenging due to these syndromes’
distinct neuro-pathologies.
The two pharmacological strategies for migraine treatment include prophylactic and
abortive agents. Prophylactic agents prevent the onset of a migraine, and include compounds that
act on diverse mechanisms including beta-blockers, alpha agonists, and antidepressants (Lewis et
al., 2004). Abortive agents are used to terminate a migraine event, and include compounds that
act as serotonin (5HT1B/1D) agonists (Tfelt-Hansen et al., 2000) and nonsteroidal antiinflammatory agents (NSAIDs) (Lewis et al., 2004). While widely utilized, all anti-migraine
compounds have limited efficacy and have extensive side effect profiles.
Most prophylactic treatments do not alleviate migraines by more than 50% over placebos
with side effects such as fatigue, nausea, and bradycardia (Parsekyan, 2000). These factors
contribute to migraineurs switching to abortive treatments. Triptans are the most frequently
prescribed abortive treatments, however, migraineurs prescribed triptans often cease taking them
due to low efficacy and adverse side effects (Messali et al., 2014) including nausea, chest
tightness, and drowsiness (Parsekyan, 2000).
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The high prevalence of migraine, the limited efficacy and side effect profile of antimigraine medication, and loss of quality of life in untreated migraine strongly argues for the
development of novel treatment strategies.
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CHAPTER 2

BACKGROUND

The bulk of drug discovery research comes from pre-clinical screening assays done with
animal models of clinical syndromes. One of the major challenges today is developing models
and screening assays in which efficacy translates into beneficial clinical effects in targeted
human populations (Mao, 2012; Willner, 1997; Nestler & Hyman, 2010). Indeed, many
screening assays fail to show such “translational relevance”. For example, the NMDA antagonist
Ketamine shows anti-hyperalgesic effects in neuropathic pain animal models but lacks efficacy
in clinical populations (Mao, 2012). This lack of translational relevance accounts in the lack of
efficacious pharmacotherapy for migraine.
A number of researchers have worked in the area to develop better clinical simulations of
a variety of clinical disorders. The general approach or method to animal model development
and validation is through endophenotypic mapping, in which homologies between a syndrome’s
etiology, symptomatology, pathophysiology, and response to treatment are “mapped” onto the
animal paradigm (van der Staay, 2006). The argument is that the animal simulation with the best
translational relevance will be one with the greater number of homologies.
A number of migraine animal models have been developed in the last decade. These
models vary based on migraine induction and behavioral endpoints. Two common methods for
migraine induction involve intracranial administration of inflammatory agents (Yan & Dussor,
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2012), or systemic administration of nitroglycerine (NTG) (Buzzi & Tassorelli, 2010). The use
of NTG is based on the observation that cardiovascular patients taking NTG for angina often
develop a migraine 2 h post NTG administration (Bank, 2001). Rodents administered NTG will
behaviorally display thermal or tactile allodynia or hyperalgesia (Pradhan et al., 2014; Costa et
al., 2005). Allodynia presents as a pain-related behavior to a previously non-painful stimulus.
Hyperalgesia presents as a heightened or exaggerated response to a painful stimulus. Several
laboratories have tried to develop clinically relevant migraine models in rats and mice and this
work is summarized below.
Tassorelli et al. (2003) sought to measure the effects of NTG on two nociceptive assays.
Rats were given either 1 NTG (10 mg/kg) administration or vehicle and tested 1 – 4 h post
injection. The assays included tail-flick and formalin tests. These researchers found that NTG
was associated with a significant decrease in tail-flick latency 4 h after injection. NTG also
elicited an increase in flinches in the formalin test 2 h post administration. It is interesting to
note that while hyperalgesia and allodynia can be detected during a migraine episode, these are
not symptoms required for clinical diagnosis, according to criteria mentioned earlier in the
ICHD, and a single headache episode is insufficient for migraine diagnosis which requires 5
episodes.
In response to some of the aforementioned issues, Pradhan et al. (2014) gave mice 5 NTG
administrations (10mg/kg NTG or vehicle) and quantified the presence of allodynia 2h post final
administration. Mice given 5 NTG episodes developed sustained mechanical hyperalgesia
compared to controls. These researchers argue that repeated NTG (rNTG) migraine episodes are
a more valid model as it better mirrors migraine frequency in clinical populations. In the context
of van der Staay’s (2006) endophenotypic mapping strategy, establishing a homology in etiology
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is an important step in model validation. However, a model’s validity is also dependent on
establishing homologies in symptoms.
Sufka et al. (2016) sought to determine whether single or rNTG migraine episodes also
influenced clinically relevant endpoints of photophobia and activity. In experiment 1, rats were
administered a single IP injection of NTG or saline and tested 2 h post injection. Behavioral
assays included the Rat Grimace Scale (RGS) (Sotocinal et al., 2011), warm-and cold-water tail
flick tests, and light/dark box (with activity measures). These researchers found that a single
NTG episode failed to affect not only measures of allodynia but also clinical endpoints of
photophobia and hypoactivity. Their findings indicate that use of a single NTG episode is
insufficient to elicit migraine-related behavior. This finding is not surprising as a minimum of 5
headache episodes are required for diagnosis of migraine.
Experiment 2 sought to determine whether rNTG episodes would affect this same
behavioral endpoint. In this study, rats were administered 1, 3, or 5 migraine episodes. Two h
post the final NTG administration, animals were given the same assays as in experiment 1.
Because in clinical populations, chronic migraineurs show higher co-morbidities with stressrelated disorders, animals were tested using the elevated plus maze (EPM) and the forced swim
test (FST) the following day. The EPM and FST are behavioral assays that quantify the presence
of anxiety and depression. The researchers found rNTG administrations did not significantly
affect any results measuring anxiety or depression suggesting this model does not represent
chronic migraine for rat
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In experiment 3, Sufka et al. explored whether the abortive treatment, sumatriptan,
would reverse behavioral responses (i.e. movement, weight loss, RGS score, and time spent in
dark portion of light/dark box) to NTG. Animals were administered 5 NTG injections. Thirty m
following the NTG injections animals were administered sumatriptan (0.3 or 1.0 mg/kg) or saline
and tested 2 h post final injection using RGS and light/dark box. Sufka et al, found animals
receiving sumatriptan spent less time in the dark portion of the light/dark box, increased in
movement, and did not lose weight compared to controls. Sufka et al. argues that rNTG
injections with these clinical endpoints and the ability of sumatriptan to reverse the behaviors
makes this migraine model more relevant than other models.
Sufka et al. show rNTG induces photophobia and hypoactivity and sumatriptan can
reverse these two clinically relevant endpoints. If the rodent migraine model mirrors the clinical
migraine picture, then the stress imposed onto the rodent will significantly affect clinically
relevant endpoints. Therefore this study utilized the chronic mild stress paradigm with the rNTG
paradigm to explore whether chronic mild stress affected activity and photophobia in NTG rats.

7

CHAPTER 3

METHODS
Male Sprague-Dawley rats (Harlan Laboratories; Indianapolis, IN, USA) weighing
approximately between 150 – 200g served as subjects for the experiment. Animals were pair
housed in 13 x 21 x 22 cm polyethylene tubs. Small igloo-type enclosures were provided in cage
to permit rats to learn to avoid light after NTG administration. These rodent igloos were PVC
pipe end caps (16.5 cm diameter x 7.5 cm tall) with an arched opening to allow entry. Food
(Teklad 7001, Teklad Diets, Madison, WI, USA) and water were available ad libitum. Overhead
florescent lighting was maintained on a 12/12h light/dark cycle with lights on at 7:00.
Migraine groups were injected with nitroglycerin (NTG; SDM®27, Copperhead
Chemical Company Inc. Tamaqua, PA, USA) diluted into propylene glycol and ethanol. Dosing
and concentrations of NTG (10 mg/kg/2ml) was determined based on previous studies (Costa,
2005; Tassorelli, 2003). Control rats were given a 50:50 solution of propylene glycol and
ethanol (PG/EtOH). Both NTG and PG/EtOH were administered via an intraperitoneal (IP)
injection. The rats received 5 injections with the final injection given on test day. There were
two days of handling between each injection.
Half of the rats were exposed to restraint stress. The restraint stress involves the animals
being restrained via a DecapiCone (Braintree Science Inc., Braintree, MA) a transparent plastic
cone. Rats were restrained for 2 h/day for 14 days. The day following the final exposure to the
restraint stress, the animals underwent behavioral assays that quantify anxiety and depression.
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The forced swim test (FST) was used to measure behavioral despair (depression). During
the FST an animal was placed into a cylinder (20 cm diameter x 35 cm tall) filled with water
maintained at 24-26°C for a 5 m test period. During the test session animals engage in these
behaviors as defined by rigorous swimming, diving, or trying to escape the apparatus. Eventually
animals engage in a floating behavior that marks the onset of a behavioral despair state which
models depression (Porsolt, 1977). The amount of time the animal spends struggling is recorded.
This time is reduced (i.e., animals enter into a behavioral despair state more quickly) when they
are exposed to a stressor.
The elevated plus maze (EPM) was used to measure anxiety-like behavior. The EPM is a
plus shaped apparatus elevated 76 cm above the ground with 4 arms, 2 of which have 19 cm side
walls while the other 2 are open and do not have side walls. In general animals avoid the open
arms because a) they are open and b) they are elevated which induces fear. Amount of time spent
in the closed arms for a 5 m test period was recorded. Animals exposed to stressors will spend
more time in the closed arm.
The Rat Grimace Scale (RGS) was used to measure pain states by facial expression. Rats
were placed in a Plexiglas chamber (31 x 22 x 26 cm) and photographed using a digital camera
and later scored by trained assistants using the RGS. This is described in detail elsewhere
(Sotocinal, 2011).
A modified light/dark box was used to measure photosensitivity and movement. Animals
were placed into a three-chamber place preference apparatus (Model # MED-CPP-013, Med
Associates Inc., St. Albans, VT, USA) that was modified into a light/dark box. The apparatus
was modified by covering the transparent lid of the black and gray chamber with heavy black
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construction paper to allow for the dark portion of the apparatus. The white chamber of
the apparatus remained uncovered to allow for a light portion. Each chamber has photo beams to
detect movement, activity, and amount of time an animal spends in that portion of the box. Once
an animal enters a chamber, the photo beams are broken and data is collected by the software for
these measures. On test days, animals were placed into the center gray chamber for a 1 m
acclamation. After the acclamation period the guillotine doors were lifted allowing the animal to
roam about the apparatus for a 10 m test period. The amount of time spent and movement counts
within each chamber was quantified by the number of beam breaks caused by the animal. Data
was collected by vendor software.
The hotplate was used to measure thermal nociception. Rats were placed into an acrylic
enclosure on a hotplate maintained at 52°C (Harvard Apparatus, Model#52-8570). Latency to
lick or flutter hind paw, or escape behavior was recorded. Animals receiving NTG that show
thermal hyperalgesia would display shorter response latencies. Animals were returned to home
cage following completion of this assay.

Procedure
Animals were randomly assigned to either non-CMS/non-NTG, non-CMS/NTG, CMS/nonNTG, or CMS/NTG groups. Animals receiving CMS were restrained for 2h/d/2w. The day
following the final exposure to restraint stress, the animals underwent behavioral assays that
quantify anxiety and depression (FST, EPM). Simultaneously, animals receiving the migraine
protocol received 5 NTG injections with the final injection given on test day (RGS, modified
light/dark box, and hotplate). There were two days of handling between each injection (see Table
1).
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Statistical Analysis
Data were screened for outliers before data analyses. This included excluding animals
with illness due to injection. Animals with distended abdomens were removed from this study
humanely euthanized. These procedures were approved by Institutional Animal Care and Use
Committee at the University of Mississippi (Protocol #13-023). The total number of animals
omitted based on these criteria equaled 2.
For analyses of anxiety, average time spent in EPM closed arm in non-CMS/CMS and
non-NTG/NTG treatment groups were conducted using a two-way analysis of variance
(ANOVA) followed by Fisher’s Least Significant Difference (LSD) post-hoc tests. A
statistically significant increase in time spent in EPM closed arm time was considered an
induction of anxiety.
For analyses of depression, average FST float time in non-CMS/CMS and nonNTG/NTG treatment groups were conducted using a two-way analysis of variance (ANOVA)
followed by Fisher’s Least Significant Difference (LSD) post-hoc tests. A statistically
significant increase in FST float time was considered an induction of depression.
For analyses of pain states, average RGS scores in non-CMS/CMS and non-NTG/NTG
treatment groups were conducted using a two-way analysis of variance (ANOVA) followed by
Fisher’s Least Significant Difference (LSD) post-hoc tests. RGS scores were averaged together
for percentage agreement between raters as well as the score assigned to the image by the raters.
A statistically significant increase in RGS scores was considered an increased state of pain.
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For analyses of photosensitivity, average time spent in light portion of light/dark box
non-CMS/CMS and non-NTG/NTG treatment groups were conducted using a two-way analysis
of variance (ANOVA) followed by Fisher’s Least Significant Difference (LSD) post-hoc tests.
A statistically significant decrease in time spent in light portion of light/dark box was considered
photosensitivity.
For analyses of movement, average number of beam breaks for non-CMS/CMS and nonNTG/NTG treatment groups were conducted using a two-way analysis of variance (ANOVA)
followed by Fisher’s Least Significant Difference (LSD) post-hoc tests. A statistically
significant decrease in number of beam breaks was considered decreased movement.
For analyses of thermal nociception, average hotplate latencies non-CMS/CMS and nonNTG/NTG treatment groups were conducted using a two-way analysis of variance (ANOVA)
followed by Fisher’s Least Significant Difference (LSD) post-hoc tests. A statistically
significant decrease in hotplate latencies was considered thermal sensitivity. Sample sizes
consisted of n=8-10.
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Table 1
Timeline of CMS and rNTG Protocol.
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CHAPTER 4

RESULTS

The effects of CMS and NTG induced migraine on endpoints of behavior in light/dark
box (i.e. photosensitivity and movement), behavioral despair (i.e. float time in forced swim test),
and nociception are summarized in Table 2. CMS did not affect escape behavior in the FST
under either migraine condition. NTG tended to reduce time spent in the light box in nonstressed animals; however, this NTG effect was not evident under stressed conditions.
Furthermore, motor activity tended to increase in stressed animals compared to non-stressed
animals; however no main effect or an interaction was found between CMS and NTG.
Nociceptive behavior was not altered under either CMS or NTG condition. A MANOVA was
conducted on endpoints quantified by the light/dark box (i.e. photosensitivity and movement).
The MANOVA failed to reveal significant main effects for stress, F (1, 31) = 1.648, 1.164 (p =
0.209, 0.208) and migraine, F (1, 31) = 1.20, 0.675 (p = .0282, 0.418) nor a significant effect for
the stress x migraine interaction, F (1, 31) = 0.263, 0.757 (p = 0.612, 0.391). A two-way
ANOVA was conducted on FST float time and nociception (i.e. hotplate latency). The two-way
ANOVA for both endpoints failed to reveal main effects for stress, F = (1, 31) = 0.032, 1.249 (p
= 0.859, 0.272) and migraine, F (1, 31) = 0.454, 0.029 (p = 0.505, 0.856) nor a significant effect
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for stress x migraine interaction, F (1, 31) = 1.175, 0.507 (p = 0.287, 0.482). Post-hoc analyses
were not conducted on these data.

Figure 1. Time (in seconds) in closed arm of Elevated Plus Maze (EPM) by CMS and NTG
groups. Data represent means ± standard error of the mean (vertical line). *Significant increase
in time in closed arms in CMS compared to their respective controls. P < 0.05. Sample sizes
were n = 8 - 10.

The effects of CMS on NTG induced migraine on endpoints of anxiety-like behavior in
the Elevated Plus maze is summarized in Figure 1. NTG did not affect amount of time spent in
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the closed arm; however, CMS tended to increase time spent in the closed arm. A twoway ANOVA was conducted on EPM data where there was no main effect for migraine, F (1,
32) =
0.113, (p = 0.739), and no effect for stress x migraine interaction, F (1, 32) = 1.061, (p =
0.311) was found; however there was a significant main effect for stress, F (1, 32) = 4.213, p <
0.05. No further post-hoc tests were conducted due to significance in a single group. This finding
indicates CMS induced an anxiety-like phase in the CMS animals despite which NTG group the
animal was placed in.
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Figure 2. Average Rat Grimace Scale (RGS) score by CMS and NTG groups. Data represent
means ± standard error of the mean (vertical line). *Significant increase in RGS score in NTG
compared to no NTG groups. P < .05. Sample sizes were n = 8 - 10.

Effects of CMS and NTG induced migraine on endpoints in the Rat Grimace Scale scores
are summarized in Figure 2. CMS did not affect RGS scores; however, NTG significantly
increased scores. A two-way ANOVA failed to reveal any significant main effect for stress, F
(1, 31) = 0.086, (p = 0.771), and an effect for stress x migraine interaction, F (1, 31) = 0.003, (p
= 0.957); however a significant main effect was revealed for migraine, F (1, 31) = 1.478, p <
0.05. These findings indicate the NTG was able to elicit a pain expression in the NTG groups.
17

Table 2
Behavioral Endpoints in Rat rNTG Model Across Stress and NTG Groups
Endpoints
FST Escape
Behavior (s)
Time Spent in
Light
Locomotor
Activity (# of
Beam Breaks)
Hot Plate
Latency (s)

No Stress
No Stress/No
No Stress/NTG
NTG
155.29
149.88
(39.60)
(36.75)
31.27
18.41
(34.15)
(17.68)
274.00
208.33
(103.64)
(133.42)
10.39
(2.11)

9.73
(2.67)

Stress
Stress/No NTG
Stress/NTG
143.36
(32.89)
35.27
(16.57)
277.70
(110.03)

166.53
(45.57)
33.70
(22.88)
301.00
(110.01)

9.03
(1.88)

9.43
(1.98)

(Values represent composite means for each group with standard deviation (SD) in parentheses.)
Sample sizes n = 8 – 10.
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CHAPTER 5

DISCUSSION

Migraineurs report that stressors increase frequency and intensity of migraine episodes;
furthermore, chronic migraineurs present increased comorbidity of stress-related disorders (i.e.,
PD, and GAD, MDD). In an attempt to further validate a rodent NTG migraine model, we
sought to determine whether repeated restraint stress altered migraine-related behavior and/or
whether repeated migraine episodes altered stress-related behavior. To test this relationship,
animals received one of the following treatment condition pairs: non-CMS/non NTG, nonCMS/NTG, CMS/non-NTG, and CMS/NTG. In non-NTG groups, we predicted the CMS
manipulation would increase time in EPM closed arms and increase FST float time. In the nonCMS groups, we predicted the NTG manipulation would increase RGS scores and decrease a)
time in the light portion of and b) total movement in the light/dark box. Finally, we predicted a
treatment interaction whereby the CMS/NTG group would further a) increase time in EPM
closed arms and b) increase FST float time compared to CMS/non-NTG group. In addition, the
CMS/NTG group would display greater RGS scores and a larger decrease in a) time in light
portion and b) total movement in the light/dark box compared to non-CMS/NTG group.
A literature shows a wide variety of stressors including single stressors, social stressors,
and psychological stressors alter EPM rodent behavior (see review, Borghans,
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2015; Chiba et al., 2012; Lapmanee et al., 2013; Leem et al., 2013). For example, Chiba et al.
(2012) found CMS administered to mice in an acrylic cylinder apparatus for 6h/1d/4w increased
EMP closed arm time. Lapmanee et al. (2013) found CMS administered to rats in a transparent
plastic container for 2h/5d/4w increased EPM closed arm time. Leem et al. (2013) found rats
restrained in a conical tube for 2h/14d increased EPM closed arm time. The present study using
the same chronic restraint protocol as employed by Leem et al. (2013) yielded similar results. In
both non-NTG and NTG-groups, CMS altered anxiety-like behavior as evidenced by more time
in EPM closed arms. However, NTG did not exacerbate CMS effects in the EPM. These findings
suggest that this recurrent NTG migraine model does not align with chronic migraine in clinical
populations but may better simulate episodic migraine.
FST float time is affected by a number of stressors including single prolonged stress,
unpredictable chronic mild stress, and predictable mild stress (Serova, 2013; Kushwah, 2016;
Leem et al., 2013; Chiba et al., 2012; Lapmanee et al., 2013). Chiba et al. (2012) found CMS
administered to mice in an acrylic cylinder apparatus for 6h/1d/4w increased FST float time.
Lapmanee et al. (2013) found CMS administered to rats in a transparent plastic container for
2h/5d/4w increased FST float time. Leem et al. (2013) found CMS administered to mice in a
conical tube for 2h/d/2w increased FST float time. The present study using a similar chronic
restraint protocol as employed by Leem et al (2013) was unable to replicate such CMS effects in
either non-NTG or NTG groups. It is unclear why this CMS protocol affected the stress endpoint
on the EPM but not FST. Further, recurrent NTG episodes were unable to affect FST endpoints
compared to non- NTG groups. It may be necessary to only see significant alterations in EPM
and FST endpoints during a migraine episode rather than from having 4 episodes during the
previous 10 days (see Table 1 for protocol). However, this is unlikely as previous research has
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shown that 1, 3 and 5 NTG episodes do not alter EPM and FST endpoints when
administered 2h before testing (Sufka et al., 2016).
Recent research suggests repeated NTG administration shows an increase in RGS scores.
Sufka et al., (2016) administered NTG 1, 3, or 5 times over a 2-week period and found that 5
NTG episodes increased RGS scores. Consistent with these findings, both non-CMS and CMS
groups that received 5 NTG episodes displayed increased RGS scores; however, the CMS did
not exacerbate RGS scores. In clinical populations, stress typically increases migraine frequency
and chronification. Taken together, these data suggest the recurrent 5 NTG model better
simulates episodic migraine.
NTG effects on photosensitivity are nuanced (Sufka et al., 2016; Farkas et al., 2016).
Sufka et al. (2016) report rats given 5 NTG administrations displayed decreased time spent in the
light portion of and decreased movement in the light/dark box. In contrast, Farkas et al. (2016)
found mice with 1 NTG administration of either Nitrolingual or Nitro Pohl (nitroglycerin
formulations) did not affect time in the light portion of light/dark box. In the current study, 5
NTG episodes did not affect either time spent in the light portion or total movement in the
light/dark box in both non-CMS and CMS groups. While these data on photosensitivity and
movement are inconsistent with Sufka et al., (2016), it is important to note difference in vehicles
used between the studies. Earlier studies have used 0.9% saline whereas the current study used a
50:50 mixture of propylene glycol and ethanol (PG/EtOH) which is the actual vehicle of NTG.
A comparison of these data to Sufka et al. (2016), reveal that PG/EtOH affect migraine related
endpoints in a manner similar to NTG groups. We address the rationale for selecting this vehicle
below and offer suggestions for future studies.
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Despite its absence as a diagnostic criterion of migraine, hyperalgesia is commonly
measured in NTG migraine models (Costa et al., 2005; Farkas et al., 2016). For example, both
rats (Costa et al., 2005) and mice (Farkas et al., 2016) show decreased tail-flick latencies post
NTG administration. The current study using 5 NTG administrations failed to detect
hyperalgesia on the hotplate test in either non-CMS or CMS groups. This may not be surprising
given all of the other migraine endpoints in this research suggest this protocol is an episodic
rather than chronic migraine model. Collectively, these findings bring into question the necessity
of such thermal nociceptive measures in NTG migraine models.
A review of the literature shows this is the first study to explore the interaction between
stress-related behavior and migraine-related behavior in an animal model of migraine. Clinicians
report chronic migraineurs have a higher comorbidity of stress-related disorders. We
hypothesized that if the 5 NTG rodent model simulates chronic migraine, then this protocol
would increase stress-related behaviors on EPM and FST. In contrast, we found that the
NTG/CMS treatment did not exacerbate either stress-related endpoints. These data suggest this 5
NTG recurrent model better simulates episodic migraine.
It is also reported that chronic migraineurs report stress exacerbates frequency and the
chronification of migraine. We hypothesized that if the 5 NTG rodent model simulates migraine,
then a CMS protocol may exacerbate migraine-related endpoints (rather than frequency). We
found that NTG/CMS treatment did not exacerbate such endpoints and leads us to infer this 5
NTG recurrent model better simulates episodic migraine.
There were a number of unexpected findings in the current work that should be addressed
and factored into future work in NTG migraine modeling. Differences between non-NTG and
NTG treatment groups on migraine-related endpoints were equivocal. We report herein that
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PG/EtOH, as an NTG vehicle, alter migraine-related endpoints in a manner similar to NTG.
Pradham et al., (2013) report no differences between saline and NTG-vehicle control groups on
tactile allodynia following a single NTG migraine episode. However, these authors do not
present data supporting this claim. Our decision to use PG/EtOH as a vehicle was based on
concerns of experts in animal migraine modeling. Our findings suggest the use of saline as the
most appropriate control in an NTG migraine model. This suggestion aligns with other wellestablished animal pain models. For example, in a model of arthritis, experimental groups
receive complete Freund’s Adjuvant (CFA) to an ankle joint while controls groups receive no
injection (Stein et al., 1988). We suggest that future research may wish to directly compare saline
and NTG-vehicle groups on migraine-related endpoints to further refine this model of episodic
migraine.
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